Taking Mounjaro with no thyroid: what you need to know

Step 1: Understand the thyroid precaution and whether it applies to you

The Mounjaro prescribing information carries a warning about thyroid C-cell tumours, based on findings in rodent studies. Those animal studies showed increased rates of thyroid C-cell tumours at doses far exceeding human therapeutic levels. It has not been established that tirzepatide causes the same effect in humans, and humans and rodents differ substantially in their C-cell biology. The NHS patient information page for tirzepatide reflects this by noting that the medicine should not be used by anyone with a personal or family history of MTC or MEN2.

Here is where the distinction matters for you. If your thyroid was removed or ablated because of MTC, the risk from any residual or hereditary predisposition is still clinically relevant even without a thyroid gland, and tirzepatide would not be prescribed. If your thyroidectomy was for papillary or follicular thyroid cancer, Hashimoto's disease, Graves' disease, a toxic nodular goitre, or another benign reason, the MTC contraindication does not apply. That does not make the decision straightforward, but it does mean the conversation with a prescriber is worth having.

A prescriber will want to know the exact reason your thyroid was removed or ablated, your oncological status if cancer was involved, and how well your current hormone replacement is controlled. Whether you can take Mounjaro if you have thyroid issues is a question we cover in detail, including the wider set of thyroid-related considerations for people weighing up whether to start treatment. More on Mounjaro and thyroid conditions generally gives background on the wider set of thyroid-related questions, including what the evidence says about Mounjaro and thyroid health for people weighing up whether to start treatment.

Step 2: Think through what having no thyroid means for levothyroxine absorption

Almost everyone who has no functioning thyroid takes daily levothyroxine. It is one of the most absorption-sensitive medicines around: the standard advice is to take it first thing in the morning, at least 30 minutes before food, away from calcium, iron, and other tablets that interfere with gut uptake.

Tirzepatide slows gastric emptying. That is part of how it reduces appetite and calorie intake, and it is also one reason the prescribing information prompts care around other oral medicines. In practice, the evidence that tirzepatide meaningfully disrupts levothyroxine absorption in people following standard dosing protocol is limited; the published literature on this combination is not extensive. What is established is that any change in gastrointestinal motility can shift thyroid-stimulating hormone (TSH) levels, sometimes enough to affect wellbeing or require a dose adjustment.

The practical upshot: if a prescriber approves tirzepatide for you, your GP or endocrinologist should know. A TSH check roughly six to eight weeks after starting, and again after any dose increase, is sensible practice. You can read about how Mounjaro may affect thyroid function for a fuller look at this interaction. Timing your levothyroxine as you normally would (consistently, on an empty stomach) remains the right approach, and the two medicines do not need to be taken at the same time.

Step 3: Raise it with the right clinicians before starting

Weight management decisions rarely sit with one clinician when you have a complex background. If your thyroid was removed as part of thyroid cancer treatment, your oncologist or endocrinologist should be part of the conversation, not told afterwards. If your situation is more straightforward, your GP still needs to know you are starting tirzepatide, partly because NHS England's guidance on weight management injections recommends GP notification as standard practice for GLP-1 receptor agonists, and partly because TSH monitoring needs coordinating somewhere.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not software) who reviews your full medical history, including any history of thyroid surgery or ablation, your current thyroid replacement dose, and any relevant oncological background. Some enquiries are better directed to your specialist first; our prescribers will say so if that is the case, rather than proceed where it would not be safe to. If you have questions before starting, our aftercare team is available seven days a week. Those of us who hear from patients on a Monday after a long weekend (or just before a bank holiday) know the timing of that first contact often has nothing to do with medical urgency and everything to do with finally finding a quiet moment. That is fine. The process works whenever you come to it.

If you would like to start your free consultation, the form covers your medical history in full, and the prescriber's review happens the same day on weekdays.

Step 4: Know what ongoing monitoring looks like

People with no thyroid who start tirzepatide are not in uncharted territory, but they do need a clear monitoring plan. The main things to watch are thyroid hormone stability, gastrointestinal tolerance (particularly in the first few weeks of each dose step), and signs that levothyroxine absorption has shifted. Fatigue, unexpected weight changes, or changes in heart rate can reflect TSH drift rather than the tirzepatide itself.

The MHRA's Black Triangle designation for Mounjaro means any suspected adverse effects (including unexpected changes in thyroid function) should be reported via the Yellow Card scheme. This is open to patients, not just clinicians, and it contributes to the ongoing safety picture for all newer medicines. Beyond thyroid monitoring, the general considerations around Mounjaro and thyroid problems are worth reading for completeness. Eligibility, ongoing suitability, and dose changes all remain clinical decisions made by your prescriber at each review.